Abstract-Large artery stiffening contributes to the pathophysiology of heart failure (HF) and associated comorbidities.
L
arge artery stiffening causes an excessive pulsatile load to the heart and to the microvasculature of various target organs. Both effects are involved in the pathophysiology of cardiac dysfunction and heart failure (HF)-associated comorbidities (such as renal dysfunction). The identification of pathways related to arterial stiffness in HF may provide novel therapeutic targets.
MGP (matrix Gla-protein) is a protein produced by chondrocytes and vascular smooth muscle cells. 1 The inactive form of MGP (dp-ucMGP [dephospho-uncarboxylated MGP]) undergoes serial posttranslational γ-glutamate carboxylation and serine phosphorylation to form active MGP. The active form of MGP is a potent inhibitor of vascular calcification. Carboxylation of dp-ucMGP is vitamin K-dependent and is thus reduced in vitamin K-deficient states.
1 Dp-ucMGP is secreted into the circulation, and an increase in its levels indicates deficient MGP activation. Recent studies in non-HF populations indicated that abnormal MGP maturation correlates with arterial stiffness in humans. 2, 3 Less information is available on the relationship between MGP and arterial stiffness in HF. HF is associated with hemodynamic abnormalities, metabolic abnormalities, renal dysfunction, and the use of multiple medications, which could impact the relationship between MGP and pulse wave velocity (PWV).
A previous study demonstrated increased levels of dpucMGP in an HF with reduced ejection fraction (HFrEF) population. 4 However, whether HF with preserved ejection fraction (HFpEF) is associated with increased dp-ucMGP levels, and more importantly, whether MGP levels correlate with arterial stiffness in subjects with HFrEF or HFpEF is unknown. This is important because HFpEF and HFrEF are different disease states, with different pathophysiology and response to therapy; furthermore, it is important to better understand HFpEF given that there are no currently available evidence-based effective pharmacological interventions for this condition.
Patients with HF often receive warfarin, a vitamin K antagonist that may inhibit MGP activation. In animal models, warfarin administration at high doses produces profound arterial calcification 5 and several lines of evidence link warfarin use to arterial calcification in humans. [6] [7] [8] [9] [10] Arterial calcification is an important contributor to arterial stiffness. 11 However, the relationship between warfarin use, MGP activation, and large artery stiffness in HF is unknown.
In this study, we aimed to (1) compare levels of plasma dp-ucMGP levels between subjects with HFpEF, HFrEF, and subjects without HF; (2) assess the relationship between dpucMGP levels and carotid-femoral PWV (CF-PWV), the noninvasive gold-standard index of large artery stiffness 12, 13 ; (3) assess the relationship between warfarin use, dp-ucMGP levels, and arterial stiffness in HF.
Methods
We prospectively enrolled a convenience sample of 348 adults at the Corporal Michael J. Crescenz VA Medical Center referred for a cardiac magnetic resonance imaging (MRI) study. The protocol was approved by the Philadelphia VA Medical Center Institutional Review Board, and all subjects provided written informed consent. The investigation conforms with the principles outlined in the Declaration of Helsinki.
The data, analytic methods, and study materials are not publicly available for purposes of reproducing the results or replicating the procedures. Such data may be made available to other researchers for collaborative research through the establishment of appropriate agreements.
Key exclusion criteria were as follows: (1) claustrophobia; (2) presence of metallic objects or implanted medical devices in body; (3) conditions that could make the measurements of CF-PWV less accurate or unreliable (ie, arrhythmia, such as atrial fibrillation); and (4) history of sarcoidosis or amyloidosis or suspected infiltrative heart disease.
To optimize case classification according to left ventricular ejection fraction (LVEF) and other cardiac parameters detailed below, we measured LVEF and cardiac structure and function using the current gold-standard method (steady-state free-precession cine cardiac MRI). HFrEF was defined as a symptomatic HF patient with a LVEF <50%. HFpEF was defined as (1) New York Heart Association Class II to IV symptoms consistent with HF; (2) LVEF >50%; (3) a mitral E wave to annular (e′) ratio >14; or at least 2 of the following: (1) a mitral E wave to annular e′ ratio >8; (2) treatment with a loop diuretic for control of HF symptoms; (3) left atrial volume index >34 mL/m 2 of body surface area; (4) NT-proBNP (N-terminal pro-B-type natriuretic peptide) level >200 pg/mL; and (5) LV mass index >149 g/m 2 in men and 122 g/m 2 in women. Subjects without HF had an LVEF >50% and no symptoms and signs consistent with HF.
CF-PWV Measurement
CF-PWV was measured using the SphygmoCor system (Atcor Medical; Sydney, Australia). Briefly, carotid-to-femoral transit time (ΔT) was computed from the foot-to-foot time difference between sequentially acquired carotid and femoral waveforms, using the intersecting tangents method and the QRS complex of the ECG as a fiducial point. The distance between the sternal notch and the carotid artery was subtracted from the distance between the sternal notch and the femoral artery (measured with rigid calipers), to estimate the path length, and CF-PWV was computed as path length/ΔT. The coefficient of variation for CF-PWV measurements in our lab is <10%.
Cardiac MRI
We measured LV mass, volume, and left atrial volume, using a 1.5 T whole-body MRI scanner (Avanto or Espree, Siemens, Malvern, PA) equipped with a phase-array cardiac coil.
LV volumes (end-diastolic and end-systolic volumes) and function (EF) were measured using steady-state free-precession cine imaging. Typical acquisition parameters were a repetition time=30.6 ms; an echo time=1.3 ms; slice thickness=8 mm; phases=30; integrated parallel imaging technique factor=2; and matrix size= 192x192.
CMR42 software (Circle CVI, Calgary, AB, Canada) was utilized to manually trace the LV short-axis cine images at the end of diastole and systole. LV mass was calculated as the difference between epicardial and endocardial volumes, multiplied by the myocardial density. Left atrial volume was calculated by averaging the volumes measured end-systole by manually tracing the left atrial endocardial border in the apical 2-chamber and 4-chamber views.
Plasma dp-ucMGP Measurement Citrate tubes were used for collection of venous blood samples at the time of enrollment. Plasma was prepared and stored at −80°C for batch analysis. A dual-antibody sandwich ELISA technique (VitaK; Maastricht University, the Netherlands) was used to measure dpucMGP. Intraassay coefficients of variation for this assay have previously been reported at 3.1% and 5.4% for lower and upper limit of normal. Interassay variation coefficients are 6.9% and 13.6% for lower and upper limits of normal. 
Statistical Methods
Our study had 80% power to detect standardized effect sizes of at least 0.15 with a 2-sided α error rate of 0.05. Continuous and categorical variables were compared between the groups using ANOVA and χ 2 tests, respectively. Given previous studies demonstrating an important influence of age, sex, race/ethnicity, and warfarin use on dp-ucMGP, 6, 7, 14 we adjusted for these factors in comparisons of dpucMGP levels between the groups, using ANCOVA. Post hoc pairwise comparisons were conducted using the Bonferroni correction method. Bivariable and multivariable linear regression models were utilized to assess independent correlates of dp-ucMGP, with adjustments for multiple potential confounders. Similarly, linear regression models were used to assess how warfarin use, dp-ucMGP levels, and various other factors relate to arterial stiffness (CF-PWV). As recommended by current guidelines, 12 these models were adjusted for mean arterial pressure and heart rate (which can affect CF-PWV independently of the underlying intrinsic material properties of the arterial wall). When required, Box-Cox transformation was applied to normalize regression model residuals. We present standardized regression coefficients for easier comparison of the magnitude of the effect of various independent variables on the dependent variable in regression models.
Results
Baseline characteristics of our participants with HFpEF and HFrEF and no HF are presented and compared in Table 1 . Most of the subjects were male, but the proportion of males was greater in the HFpEF group and lower in the HFrEF group. Compared with the other groups, subjects with HFpEF were significantly older, demonstrated a much greater body mass index, lower estimated glomerular filtration rate (eGFR), lower serum magnesium, and the highest prevalence of diabetes mellitus (69.79%) and hypertension (90.62%). The prevalence of coronary artery disease was highest in HFrEF (52.83%). LV mass was increased in both HFpEF and HFrEF, without significant differences between HFpEF and HFrEF, whereas LV end-diastolic volume was significantly greater in HFrEF than in HFpEF. A greater percentage of HFpEF and HFrEF subjects used β-blockers, aspirin, and furosemide as well, whereas insulin use was approximately twice as prevalent in HFpEF (32.29%) compared with either HFrEF (15.09%) or subjects without HF (14.57%). Figure 1 shows mean dp-ucMGP levels in patients without HF, HfpEF, and HFrEF. There were significant between-group differences in dp-ucMGP levels (P=0.0067). In post hoc pairwise comparisons, dp-ucMGP levels were significantly greater in HFpEF (549 pmol/L; 95% CI, 455-643 pmol/L) and HFrEF (582 pmol/L; 95% CI, 444-721 pmol/L) compared with controls (426 pmol/L; 95% CI, 377-475 pmol/L), without significant differences between the 2 HF groups.
Dp-ucMGP Levels in HF

Multivariable Correlates of dp-ucMGP
We assessed the presence of HFpEF or HFrEF and various other covariates as correlates of dp-ucMGP levels in a linear regression model (Table 2) , which also included age, sex, race/ ethnicity, body mass index, systolic blood pressure, history of hypertension, coronary artery disease, diabetes mellitus, warfarin use, and serum calcium, magnesium, and phosphorus. Standardized regression coefficients and 95% CIs for all independent variables are shown in Table 2 . Values of standardized regression coefficients and 95% CIs for significant independent correlates of dp-ucMGP levels in this model are shown in Figure 2A . In this multivariable model, variables significantly associated with dp-ucMGP included the presence of HFpEF (stan- Because renal dysfunction has been recently shown to be independently associated with dp-ucMGP, 15 we also constructed a model additionally adjusted for eGFR (Table 3 and Figure 2B ). In this model, eGFR was significantly associated with dp-ucMGP (standardized β, −0.24; 95% CI, −0.34 to −0.13; P<0.0001). HFrEF remained significantly associated with dp-ucMGP (standardized β, 0.13; 95% CI, 0.024-0.23; P=0.015), whereas HFpEF was no longer significantly associated with dp-ucMGP (standardized β, 0.08; 95% CI, −0.03 to 0.19; P=0.175). In this model, warfarin use, age, male sex, and African-American race remained significantly associated with dp-ucMGP.
Relationship Between dp-ucMGP and CF-PWV
In unadjusted analyses, dp-ucMGP levels were positively associated with CF-PWV (standardized β, 0.31; 95% CI, 0.19-0.42; P<0.0001). Similarly, in analyses restricted to patients with HF (either HFpEF or HFrEF), dp-ucMGP levels were positively associated with CF-PWV (standardized β, 0.34; 95% CI, 0.16-0.52; P=0.0002). There was no interaction between either HFpEF (P=0.37) or HFrEF status (P=0.69) and dp-ucMGP as determinants of CF-PWV.
In a model that adjusted for age, sex, race/ethnicity, mean arterial pressure, heart rate, HF group membership, body mass index, history of hypertension, coronary artery disease, diabetes mellitus, warfarin use, serum calcium, magnesium, and phosphorus, and estimated GFR, dp-ucMGP remained significantly associated with CF-PWV (standardized β, 0.18; 95% CI, 0.03-0.34; P=0.023).
In analyses restricted to subjects with HF, after adjustment for age, sex, race/ethnicity, mean arterial pressure, heart rate, HF group membership, body mass index, history of hypertension, coronary artery disease, diabetes mellitus, warfarin use, serum calcium, magnesium, and phosphorus, and eGFR, BMI indicates body mass index; CAD, coronary artery disease; DM, diabetes mellitus; dp-ucMGP, dephospho-uncarboxylated matrix Gla-protein; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction. Multivariable model showing correlates of dp-ucMGP (dephospho-uncarboxylated matrix Gla-protein). A, Without adjustment for estimated glomerular filtration rate (eGFR). B, With further adjustment for eGFR. Standardized regression coefficients and 95% CIs are shown. HFpEF indicates heart failure with preserved ejection fraction; HfrEF, heart failure with reduced ejection fraction. Figure 1 . Comparison of dp-ucMGP (dephospho-uncarboxylated matrix Gla-protein) levels between subjects with no heart failure (HF), HF with reduced ejection fraction (HFrEF), and HF with preserved ejection fraction (HFpEF), adjusted for age, sex, race/ethnicity, and warfarin use. dp-ucMGP was significantly associated with CF-PWV (standardized β, 0.32; 95% CI, 0.04-0.61; P=0.026).
Relationship Between Warfarin Use, dp-ucMGP, and CF-PWV In addition to being associated with dp-ucMGP levels, warfarin use was also independently associated with CF-PWV. In a model that adjusted for age, sex, race/ethnicity, mean arterial pressure, heart rate, HF group membership, body mass index, history of hypertension, coronary artery disease, diabetes mellitus, warfarin use, serum calcium, magnesium, and phosphorus, and eGFR, warfarin use was significantly associated with CF-PWV (standardized β, 0.13; 95% CI, 0.006-0.26; P=0.041). After further adjustment for dp-ucMGP levels, warfarin was no longer associated with CF-PWV (standardized β, 0.04; 95% CI, −0.12 to 0.19; P=0.63).
Discussion
In this study, we investigated the association between plasma levels of dp-ucMGP (a marker of vitamin K-dependent activation of MGP, a potent inhibitor of vascular calcification), HF, and large artery stiffness (CF-PWV). Our study demonstrates that dp-ucMGP levels are significantly increased in subjects with both HFpEF and HFrEF in comparison to individuals without HF. We found that dp-ucMGP was significantly associated with CF-PWV after adjusting for multiple potential confounders in regression analyses, which was also true in analyses restricted to subjects with HF. Finally, we demonstrate that warfarin use is independently associated with greater large artery stiffness. Our findings are consistent with the known vitamin K-dependent activation of MGP and its inhibitory role on arterial calcification and support the paradigm that poor activation of MGP in the vascular wall is related to large artery stiffening.
Dp-ucMGP, HF, and Arterial Stiffness
Recent reports demonstrated a positive relationship between dp-ucMGP levels and CF-PWV in a general population sample, in patients with type 2 diabetes mellitus and in patients with mild-to-moderate renal dysfunction without HF. 14, 15 A recent study also demonstrated an association between E/e′ and dpucMGP in a general population sample without HF, suggesting that a poor vitamin K status could constitute an early risk factor for the development of diastolic dysfunction. 16 To the best of our knowledge, only one previous study has assessed dp-ucMGP levels in HF patients. This study included subjects with HFrEF and demonstrated increased dp-ucMGP levels in this population. 4 Our study is the first to compare levels of dp-ucMGP in HFpEF and HFrEF and to establish a relationship between dp-ucMGP and large artery stiffness in subjects with HF. We demonstrate increased dp-ucMGP levels in both HFpEF and HFrEF. Interestingly, this association was independent of multiple confounders other than renal dysfunction in both types of HF; however, in HFpEF (but not in HFrEF), it was not independent of renal function. HFpEF and HFrEF constitute different conditions with different pathophysiologic contributors and response to therapy. Comorbidities, such as renal dysfunction, are thought to play an important role in the pathophysiology of HFpEF. 17 Therefore, the fact that the difference in dp-ucMGP levels was not independent of renal dysfunction may be because of the known association of HFpEF with chronic kidney disease (which was also evident in our study sample and may primarily be responsible for increased dp-ucMGP levels in HFpEF), or alternatively, to the fact that patients with HFpEF who exhibit deficient MGP activation are more prone to developing progressive renal dysfunction from arterial stiffening. Although our cross-sectional study cannot assess these temporal relationships, both scenarios are plausible. A recent animal model demonstrated intrinsic abnormalities in vitamin K metabolism even in early chronic kidney disease, 18 and renal dysfunction has recently been shown to be strongly and independently associated with dp-ucMGP levels. 15 Yet, deficient activation of MGP, with subsequent aortic calcification and stiffening, has the potential to promote the progression of renal dysfunction on one hand 19 and excessive myocardial pulsatile load (which can contribute to myocardial remodeling, dysfunction, and the development of HFpEF) on the other. 20, 21 Large artery stiffness and the associated pulsatile arterial hemodynamic dysfunction are implicated in the pathophysiology of HFpEF [20] [21] [22] [23] [24] [25] [26] [27] [28] through effects on LV pulsatile load, the timing of wave reflections, and central pressure and flow pulsatility, which in turn may promote comorbidities such as cognitive dysfunction 29 and particularly renal dysfunction. 12, [30] [31] [32] [33] [34] Regardless of the primary cause, our findings demonstrate that patients with HFpEF, like their HFrEF counterparts, exhibit abnormal vitamin K-dependent MGP activation, which in turn correlates with large artery stiffness. To date, effective pharmacological interventions to improve BMI indicates body mass index; CAD, coronary artery disease; DM, diabetes mellitus; dp-ucMGP, dephospho-uncarboxylated matrix Gla-protein; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction.
outcomes in HFpEF are not available. Therefore, the novel identification of specific pathways that may play a role in the underlying pathophysiology of HFpEF is important, particularly, if they can be targeted with available pharmacological agents. Vitamin K2 supplementation has been shown to reduce dp-ucMGP levels, indicating that it exerts a positive effect on MGP maturation/carboxylation, consistent with its known biologic role. 35, 36 Whether vitamin K2 supplementation can reduce or prevent large artery stiffening in subjects with or at risk for HFpEF or HFrEF remains to be studied in randomized trials.
We found a relationship between warfarin use and large artery stiffness (CF-PWV). It is known that warfarin interferes with vitamin K epoxide reductase in the vitamin K cycle, thereby interfering with the activation of VKDPs (vitamin K-dependent proteins), such as MGP, which leads to increased levels of inactive MGP (dp-ucMGP). 37, 38 We report an association between warfarin with increased dp-ucMGP levels in HF and demonstrate that warfarin use is associated with increased large artery stiffness (CF-PWV) in HF. This relationship was eliminated after adjustment for dp-ucMGP levels. These findings support the importance of poor activation of MGP in the vascular wall as an underlying factor in large artery stiffening. It is possible that warfarin use may potentiate this sequence of deleterious events by interfering with MGP activation. Given the millions of patients with HF and other conditions currently being treated with warfarin and the increasing availability of direct oral anticoagulants, this off-target effect of warfarin may have important clinical implications. Not only could the use of direct oral anticoagulants avoid warfarin-induced effects on vitamin K-dependent arterial calcification and stiffening but the potential benefits of vitamin K2 supplementation could also be extended to patients with HF who require chronic anticoagulation. These important clinical issues need to be addressed in future prospective studies.
Strengths and Limitations
Our study should be interpreted in the context of its strengths and limitations. Strengths of our study include the inclusion of a multiethnic population of patients and the inclusion of both HFpEF and HFrEF. We used high-fidelity carotid and femoral tonometry for measurements of CF-PWV, which is considered the gold-standard noninvasive approach for the noninvasive assessment of large artery stiffness. 12 We utilized cardiac MRI to accurately assess cardiac structure and function, and precisely quantify LVEF, which is critical for HF case classification. Our study also has some limitations. Consistent with the demographics of patients in a VA Medical Center, our sample was composed predominantly of males. Finally, this was a cross-sectional investigation, which provides evidence of associations, rather than direct causal inferences. However, our observations and hypotheses were based on and should be interpreted in the context of the biologic effects of dp-ucMGP that impact arterial stiffness and the well-established effects of warfarin on vitamin K-dependent protein carboxylation. However, future prospective longitudinal studies in larger cohorts are needed to demonstrate the causal relationship between dp-ucMGP and HF.
Perspectives
In summary, we demonstrate that both HFpEF and HFrEF are associated with greater dp-ucMGP levels, indicating a deficient vitamin K-dependent activation of MGP, an inhibitor of arterial calcification. We further demonstrate that dp-ucMGP levels are independently associated with large artery stiffening in HF and that warfarin use is associated with arterial stiffness. Interpreted in the context of the biologic role of MGP, our observations support a role for deficient vitamin K-dependent MGP activation in large artery stiffening in human HF. Warfarin use may exert deleterious effects on arterial stiffness via inhibition of vitamin K-dependent MGP activation, which has important clinical implications. Future studies (including randomized trials) should examine the potential therapeutic implications of avoidance of warfarin on arterial calcification and stiffening and of vitamin K2 supplementation in patients with or at risk for HF.
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